1.89 USD
-0.21
10.00%
At close May 9, 4:00 PM EDT
1 day
-10.00%
5 days
-21.58%
1 month
54.92%
3 months
-41.30%
6 months
-56.25%
Year to date
-55.42%
1 year
-88.55%
5 years
119.49%
10 years
-86.45%
 

About: Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Employees: 33

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

650% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 2

29% more funds holding

Funds holding: 31 [Q3] → 40 (+9) [Q4]

4.25% more ownership

Funds ownership: 33.62% [Q3] → 37.87% (+4.25%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

9% less capital invested

Capital invested by funds: $10.8M [Q3] → $9.82M (-$1.02M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16
747%
upside
Avg. target
$16
747%
upside
High target
$16
747%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Edward White
16% 1-year accuracy
22 / 135 met price target
747%upside
$16
Buy
Maintained
31 Mar 2025

Financial journalist opinion

Based on 5 articles about CRIS published over the past 30 days

Neutral
PRNewsWire
5 days ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass. , May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant").
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
5 days ago
Curis, Inc. (CRIS) Q1 2025 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Ahmed Hamdy - Chief Medical Officer Jonathan Zung - Chief Development Officer Conference Call Participants Li Watsek - Cantor Fitzgerald Kripa Devarakonda - Truist Securities Operator Good morning ladies and gentlemen and welcome to the Curis Provides First Quarter 2025 Business Update Conference Call. At this time, all lines are in listen-only mode.
Curis, Inc. (CRIS) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
5 days ago
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $2.05 per share a year ago.
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates
Neutral
PRNewsWire
5 days ago
Curis Provides First Quarter 2025 Business Update
Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis Provides First Quarter 2025 Business Update
Neutral
PRNewsWire
1 week ago
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
LEXINGTON, Mass. , April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m.
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
Neutral
PRNewsWire
1 month ago
Curis to Present at Upcoming Healthcare Conference in April
LEXINGTON, Mass. , April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation.
Curis to Present at Upcoming Healthcare Conference in April
Neutral
Seeking Alpha
1 month ago
Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President and CEO Jonathan Zung - Chief Development Officer Conference Call Participants Sean McCutcheon - Raymond James Li Watsek - Cantor Fitzgerald Ed White - H.C. Wainwright Operator Good morning, and welcome to Curis's Fourth Quarter 2024 Business Update Call.
Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
Curis Provides Fourth Quarter 2024 Business Update
FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis Provides Fourth Quarter 2024 Business Update
Neutral
PRNewsWire
1 month ago
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
LEXINGTON, Mass. , March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m.
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
Neutral
PRNewsWire
5 months ago
Curis Announces Additional Data from TakeAim Leukemia Study
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.
Curis Announces Additional Data from TakeAim Leukemia Study
Charts implemented using Lightweight Charts™